Royal Bank of Canada
LFCR icon

Royal Bank of Canada’s Lifecore Biomedical LFCR Stock Holding History

Royal Bank of Canada’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2K Sell
518
-755
-59% -$5.21K ﹤0.01% 6713
2025
Q4 		$10K Sell
1,273
-121,724
-99% -$900K ﹤0.01% 6415
2025
Q3 		$905K Sell
122,997
-1,353
-1% -$10.2K ﹤0.01% 4066
2025
Q2 		$1.01M Buy
124,350
+106,855
+611% +$720K ﹤0.01% 3889
2025
Q1 		$123K Sell
17,495
-15,151
-46% -$94.2K ﹤0.01% 5082
2024
Q4 		$243K Buy
32,646
+29,637
+985% +$189K ﹤0.01% 4656
2024
Q3 		$16K Buy
3,009
+1,005
+50% +$5.25K ﹤0.01% 6177
2024
Q2 		$10K Sell
2,004
-124,996
-98% -$740K ﹤0.01% 6338
2024
Q1 		$674K Buy
127,000
+21,093
+20% +$151K ﹤0.01% 3762
2023
Q4 		$655K Sell
105,907
-17,685
-14% -$123K ﹤0.01% 4027
2023
Q3 		$933K Sell
123,592
-23,409
-16% -$214K ﹤0.01% 3495
2023
Q2 		$1.42M Sell
147,001
-1,466
-1% -$8.95K ﹤0.01% 3112
2023
Q1 		$561K Sell
148,467
-2,228
-1% -$12.4K ﹤0.01% 3775
2022
Q4 		$977K Buy
150,695
+3,376
+2% +$27.8K ﹤0.01% 3522
2022
Q3 		$1.31M Buy
147,319
+170
+0.1% +$1.73K ﹤0.01% 3203
2022
Q2 		$1.47M Buy
147,149
+43,641
+42% +$432K ﹤0.01% 3174
2022
Q1 		$1.2M Sell
103,508
-3,814
-4% -$42.5K ﹤0.01% 3493
2021
Q4 		$1.19M Buy
107,322
+2,266
+2% +$22K ﹤0.01% 3630
2021
Q3 		$969K Buy
105,056
+13,954
+15% +$152K ﹤0.01% 3729
2021
Q2 		$1.02M Buy
91,102
+8,199
+10% +$94.5K ﹤0.01% 3620
2021
Q1 		$878K Buy
82,903
+30,429
+58% +$342K ﹤0.01% 3702
2020
Q4 		$570K Buy
52,474
+12,454
+31% +$129K ﹤0.01% 4026
2020
Q3 		$389K Buy
40,020
+39,956
+62,431% +$381K ﹤0.01% 4075
2020
Q2 		$1K Buy
+64
New +$660 ﹤0.01% 6448
2020
Q1 		– Sell
-1,404
Closed -$16K – 6865
2019
Q4 		$16K Buy
+1,404
New +$14.9K ﹤0.01% 5955
2019
Q2 		– Sell
-298,473
Closed -$3.67M – 7029
2019
Q1 		$3.67M Sell
298,473
-80,244
-21% -$980K ﹤0.01% 2240
2018
Q4 		$4.48M Sell
378,717
-100,529
-21% -$1.38M ﹤0.01% 2071
2018
Q3 		$6.9M Sell
479,246
-117,119
-20% -$1.62M ﹤0.01% 1872
2018
Q2 		$8.88M Sell
596,365
-163,797
-22% -$2.28M ﹤0.01% 1613
2018
Q1 		$9.92M Sell
760,162
-13,393
-2% -$176K ﹤0.01% 1547
2017
Q4 		$9.75M Sell
773,555
-44,395
-5% -$561K ﹤0.01% 1629
2017
Q3 		$10.6M Sell
817,950
-77,274
-9% -$1.02M 0.01% 1504
2017
Q2 		$13.3M Sell
895,224
-2,643
-0.3% -$36.8K 0.01% 1322
2017
Q1 		$10.8M Sell
897,867
-24,454
-3% -$310K 0.01% 1447
2016
Q4 		$12.7M Sell
922,321
-102,442
-10% -$1.42M 0.01% 1338
2016
Q3 		$13.7M Sell
1,024,763
-38,530
-4% -$467K 0.01% 1243
2016
Q2 		$11.4M Sell
1,063,293
-1,644
-0.2% -$18.1K 0.01% 1363
2016
Q1 		$11.2M Sell
1,064,937
-172,210
-14% -$1.89M 0.01% 1314
2015
Q4 		$14.6M Sell
1,237,147
-21,616
-2% -$265K 0.01% 1171
2015
Q3 		$14.7M Buy
1,258,763
+41,805
+3% +$554K 0.01% 936
2015
Q2 		$17.6M Buy
1,216,958
+99,067
+9% +$1.43M 0.01% 910
2015
Q1 		$15.6M Buy
1,117,891
+228,680
+26% +$3.16M 0.01% 973
2014
Q4 		$12.3M Sell
889,211
-47,409
-5% -$613K 0.01% 1104
2014
Q3 		$11.5M Buy
936,620
+10,664
+1% +$133K 0.01% 1125
2014
Q2 		$11.6M Buy
925,956
+18,281
+2% +$215K 0.01% 1141
2014
Q1 		$10.1M Buy
907,675
+129,772
+17% +$1.42M 0.01% 1155
2013
Q4 		$9.43M Buy
777,903
+191,115
+33% +$2.28M 0.01% 1228
2013
Q3 		$7.16M Buy
586,788
+426,210
+265% +$5.95M 0.01% 1334
2013
Q2 		$2.12M Buy
+160,578
New +$2.22M ﹤0.01% 2011

Other funds holding LFCR

2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return
3C
325 Capital New York $274M AUM 49.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GC
Grizzlyrock Capital Chicago, Illinois $126M AUM 11.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada's LFCR Position: Q1 2026 in Review

Royal Bank of Canada reduced its Lifecore Biomedical (LFCR) stake by 59% in Q1 2026, selling an estimated $5.21K and leaving 518 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #6713.

Royal Bank of Canada first reported a position in LFCR in Q2 2013 and has held it in 49 quarters since. The position peaked at $17.6M in Q2 2015. 105 funds tracked by Wall St. Rank hold LFCR as of Q1 2026.

  • Royal Bank of Canada held 518 shares of Lifecore Biomedical worth $2K as of Q1 2026.
  • Royal Bank of Canada sold 755 Lifecore Biomedical shares in Q1 2026, an estimated $5.21K.
  • Lifecore Biomedical made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6713 holding.
  • Royal Bank of Canada first reported a position in Lifecore Biomedical in Q2 2013 and has held it in 49 quarters since.
  • Royal Bank of Canada's Lifecore Biomedical position peaked at $17.6M in Q2 2015.
  • 105 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.